PROFIT ESTIMATES
-
Indian drugmaker Lupin misses quarterly profit estimates as costs rise
Indian generic drugmakers Dr. Reddy's Laboratories, Cipla and Sun Pharmaceutical Industries have benefited from strong sales and price recovery in the key U.S. market amid buoyant demand for their generic versions of the blockbuster cancer drug, Revlimid.
-
Zimmer Biomet beats Q1 profit estimates on robust demand for knee, hip devices
-
HCA beats first-quarter profit estimates on higher patient admissions
-
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
-
J&J beats first-quarter profit estimates on cancer drugs strength
-
Humana raises 2023 profit view on government insurance strength
Advertisement
Advertisement